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Abstract
Type 2 diabetes is a complex disease usually diagnosed with little regard to aetiology. In the broader sense, it is a mix of different
clearly defined aetiologies, such as monogenic diabetes, that we need to be better at identifying as this has major implications for
treatment and patient management. Beyond this, however, type 2 diabetes is a highly heterogeneous polygenic disease. This
review outlines the recent developments that recognise this heterogeneity by deconvoluting the aetiology of type 2 diabetes into
pathophysiological processes, either by measuring physiological variables (such as beta cell function or insulin resistance) or
using partitioned polygenic scores, and addresses recent work that clusters type 2 diabetes into distinct subgroups. Increasing
evidence suggests that considering the aetiological components of type 2 diabetesmatters, in terms of progression rates, treatment
response and complications. In other words, clinicians need to recognise that type 2 diabetes is multifaceted and that its
characteristics are important for how patients are managed.
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Introduction
Diabetes is simply diagnosed on the basis of hyperglycaemia,
yet there are multiple complex aetiological processes that re-
sult in this diagnostic hyperglycaemia. These processes influ-
ence the phenotype of the diabetes at presentation and how the
diabetes subsequently behaves in terms of progression, drug
response and, probably, microvascular and macrovascular
complications. The most obvious aetiological difference is
the process of autoimmune destruction of beta cells, resulting
in type 1 diabetes. Thus a good (but not perfect) diagnostic
marker for type 1 diabetes is the presence of pancreatic auto-
antibodies in the blood. Other aetiological processes can be
driven by single gene defects causing monogenic diabetes,
such as MODY. Here again there is a (relatively) simple diag-
nostic test: sequencing the known monogenic diabetes genes
and the identification of a pathological variant. In fact, we can
dissect out the aetiology of diabetes for all instances where
there is a diagnostic test (e.g. type 1 diabetes [pancreatic anti-
bodies], haemochromatosis [ferritin, gene sequencing],
Cushing’s syndrome [dexamethasone suppression test],
MODY [gene sequencing], etc.) However, what is the diag-
nostic test for type 2 diabetes? There is none, other than by
exclusion of other causes. This would suggest that the
(non-)diagnostic category of type 2 diabetes is ripe for dissec-
tion by finding diagnostic biomarkers for subtypes of individ-
uals with diabetes currently falling within this type 2 diabetes
category. An alternative view is that the lack of any key diag-
nostic features reflects the true polygenic nature of common
complex diseases and traits. We readily accept that height is
polygenic and not made up of different subtypes of height
(other than rare monogenic syndromes) so why is this not
the case for type 2 diabetes? This review will address the
complex multifaceted nature of type 2 diabetes, which in the
real world reflects a mix of missed type 1 diabetes, monogenic
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diabetes and other diagnosable aetiologies, potentially in-
cludes a small fraction of yet to be discovered monogenic
diabetes subtypes or other rare aetiologies, and includes a
large group of individuals with true type 2 diabetes within
whom there is considerable phenotypic variation.
Type 2 diabetes? First exclude known
aetiologies
Before we can start to consider the multiple faces of true type
2 diabetes it is important to recognise that a proportion of the
individuals considered to have type 2 diabetes may have an-
other aetiology that has not been diagnosed. There is much
written on this, and this is not the focus of the review.
However, it is worth making a few key points. First, an elegant
paper utilising a type 1 diabetes genetic risk score in the UK
Biobank cohort established that type 1 diabetes occurs at the
same incidence throughout life, supporting the need to con-
sider type 1 diabetes as an aetiology of diabetes at any age [1].
Second, there is large heterogeneity by region across the UK
[2] (and the world) in genetic testing for monogenic diabetes,
reflecting the difficulties of differentiating these individuals
from those with type 1 or type 2 diabetes, yet we know that
making a diagnosis of monogenic diabetes matters, as some
patients may be able to transition off insulin treatment [3, 4].
Whilst monogenic diabetes is relatively rare, accounting for
about 3% of diabetes cases diagnosed in individuals under
30 years of age, the implications for those affected are life
changing. A diagnostic pipeline utilising the measurement of
C-peptide and pancreatic autoantibodies to select individuals
with high probability of monogenic diabetes results in im-
proved diagnosis of monogenic diabetes and type 1 diabetes
[5]. Third, there is increasing recognition of the need to get the
diagnosis right at, or close to, diagnosis, and a number of
studies now highlight how discriminatory the combination
of clinical features, pancreatic autoantibodies and a type 1
diabetes genetic risk score are in diagnosing type 1 diabetes
[6, 7]. The Exeter team have incorporated risk calculators for
MODY and for type 1 diabetes within their ‘Diabetes
Diagnostics’ app (via apple and android devices) or available
at https://www.diabetesgenes.org/mody-probability-
calculator/. With increasing application of these diagnostic
biomarkers to appropriately diagnose type 1 and monogenic
diabetes, we should see a reduction in the number of
individuals with an incorrect label of type 2 diabetes.
The many faces of type 2 diabetes: multiple
rare subtypes?
Let’s now assume that we have excluded all individuals with a
diagnosable aetiology. As outlined in the introduction, it is
possible that some or all of the remaining individuals may even-
tually all be split into subgroups of as-yet-unknown aetiology.
Over the last 10 years, genome-wide association studies (GWAS)
have identified multiple common aetiological variants, each of
small effect and in sum only explaining a small percentage of the
heritability of diabetes. It was assumed that the missing heritabil-
ity was due to multiple low-frequency and rare variants that were
not being picked up in the GWAS. However, recent large-scale
sequencing [8] and high-density imputation in nearly 1 million
people (with and without diabetes) [9] has established that whilst
rare aetiological variants can be found, they explain only a little
of the phenotypic variance in type 2 diabetes, with by far the
majority of the genetic variance being explained by multiple
(potentially thousands) common variants. The latest study iden-
tified 80 rare variants and low-frequency variants, which in total
explained 1.1% of the phenotypic variance; by contrast the 323
common variants in total explained 16.3% of the phenotypic
variance [9]. Interestingly, the 2.5% of the population who are
at genetically highest risk (using the top 130,000 SNPs in a
polygenic risk score) have a 9.4-fold increased risk for diabetes
compared with those in the lowest 2.5% of the polygenic risk
score, equating to a lifetime risk of 59.7% in the highest risk
group vs 6.7% in the lowest risk group in the UK population.
This highlights how combining these commonvariants can begin
to explain large differences in diabetes risk.
Whilst these large-scale population genetics studies estab-
lish that type 2 diabetes is not a composite of multiple rare
subtypes, low-frequency variants of large effect have been
identified and in isolated populations these can rise to high
frequency and explain a large proportion of diabetes risk. In
these populations it is reasonable to redefine the aetiological
subtype of a group of individuals previously labelled as hav-
ing type 2 diabetes on the basis of their genetic aetiology. This
is beautifully highlighted in genetic studies of the Inuit popu-
lation in Greenland [10]. Here, GWAS and exome sequencing
identified a nonsense mutation in TBC1D4 (also called
AS160). This variant is present in 14% of the Inuit population,
with those homozygous for the variant having a tenfold in-
creased risk for type 2 diabetes. Overall this variant accounts
for 10% of diabetes in the Inuit population (a large genetically
defined subtype of diabetes) [10]. As TBC1D4 is involved in
insulin-mediated glucose uptake in muscle (via GLUT4),
there is a distinct physiological phenotype among these indi-
viduals, who have marked postprandial hyperglycaemia. This
raises the potential for a novel targeted treatment for this sub-
type of diabetes, traditionally treated according to standard
type 2 diabetes guidelines.
Heterogeneity in type 2 diabetes
Beyond these isolated populations, we have established that
type 2 diabetes is indeed a complex polygenic disease, with
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limited contribution from low-frequency variants. There re-
mains considerable variation in the phenotype of individuals
with type 2 diabetes, driven of course not only by genetic
variation but also by variation in lifestyle and other environ-
mental exposures. In a recent review, McCarthy introduced
the concept of the palette model of diabetes [11] in which
people develop type 2 diabetes as a result of defects in multi-
ple aetiological pathways. Many of these pathways are likely
to be currently unmapped but by way of example we can label
these processes: beta cell function, beta cell mass, insulin ac-
tion, glucagon secretion/action, incretin secretion/action and
fat distribution (Fig. 1). Each person with type 2 diabetes
develops diabetes due to a combination of defects in these
pathways. For many people the defect in each pathway may
be subtle but, with sufficient pathways affected, diabetes re-
sults. For others, diabetes may result in a more extreme defect
in one or two pathways (e.g. extreme beta cell dysfunction or
severe lipodystrophy). In McCarthy’s palette model, if each
pathway is given a colour, then individuals with diabetes can
be represented by different shades reflecting the relative con-
tribution of each pathophysiological process to their diabetes.
Given a putative large number of pathways, most individuals
would be represented by a brown colour, reflecting the small
contribution made by each (or most) pathway(s). An alterna-
tive way to represent this would be if each person were plotted
in a multidimensional space, with each axis reflecting the
pathophysiological processes. In this context, is it possible to
take a population of individuals with type 2 diabetes, map
them in this space and deconvolute their aetiological
processes? If so, can we use this to understand and/or predict
the diabetes phenotype with respect to progression, treatment
response and outcome? As outlined in Fig. 1, there are a num-
ber of routes to deconvolute the underlying aetiological mech-
anisms: (1) directly measure the physiological processes,
where these are measurable, and along with clinical variables
determine the relative contribution of each process to an indi-
vidual’s phenotype; (2) measure the underlying genetic con-
tribution, where the genetic variants are partitioned into
groups reflecting the underlying aetiological process
(partitioned polygenic scores); (3) measure an intermediate
phenotype, such as captured by the metabolome, proteome
or one of many such ‘molecular signatures’, that integrates
both genetic and lifestyle factors and (4) measure and combine
all of the above in an integrative multi-omic approach.
Deconvoluting the pathways contributing
to type 2 diabetes
Clinical and physiological measures The All New Diabetes in
Scania (ANDIS) study is a large study of more than 14,000
individuals, recruited at or close to diagnosis of diabetes, with
insulin, fasting glucose and antibodies measured at recruit-
ment [12]. This unique resource has enabled a large-scale
study aiming to dissect out aetiological mechanisms of all
diabetes (including traditional type 1 and type 2 diabetes),
with a view to grouping individuals of similar aetiology and
mapping the resulting aetiological ‘subtypes’ to outcome.
Fig. 1 Deconvoluting the diabetes component pathways. The McCarthy
palette model of diabetes represents each person as a colour, resulting
from different contributions of the colours representing the various path-
ophysiological processes that can contribute to diabetes. It is possible to
deconvolute these pathways (i.e. determine the underlying contribution
made by each process) by measuring the processes directly (where pos-
sible), by measuring the underlying genetic contribution, or bymeasuring
the intermediate metabolic phenotype (i.e. metabolites or gene
expression); all three strategies could be combined in an integrative
multi-omic approach. To convert values for HbA1c in % into mmol/mol,
subtract 2.15 andmultiply by 10.929. Adapted fromMcCarthy [11] under
the terms of the Creative Commons Attribution 4.0 International License
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in anymedium. This figure is available
as a downloadable slide
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Ahlqvist et al. used hierarchical and k-means clustering of
diabetes patients using age of diagnosis, HbA1c at diagnosis,
BMI, beta cell function (HOMA-B), insulin sensitivity
(HOMA-S) and presence or absence of GAD antibodies
[12]. They identified five subtypes of diabetes, which they
termed severe autoimmune diabetes (SAID), otherwise
known as type 1 diabetes, severe insulin-deficient diabetes
(SIDD), severe insulin-resistant diabetes (SIRD), mild
obesity-related diabetes (MOD) and mild age-related diabetes
(MARD), and demonstrated that individuals allocated to these
clusters have different characteristics. For example, the SIDD
cluster progress quickly to insulin treatment and are more
prone to retinopathy and the SIRD group are more prone to
nephropathy. An extended critique of this analysis is beyond
the scope of this review but there are few important points to
address. This is an exciting study reporting, for the first time,
the mapping of individuals with type 2 diabetes on a scale
according to these key clinical and physiological variables at
diagnosis. The fact that there is a distribution of individuals
along these pathophysiological pathways is unsurprising (i.e.
there are people with beta cell-deficient diabetes and people
with insulin-resistant diabetes) but this study does show how
type 2 diabetes varies in underlying aetiological processes
(which can be determined by measuring some simple vari-
ables involved in the pathogenesis of diabetes) and how this
impacts on the diabetes phenotype. However, we need to be
cautious about assigning individuals to one aetiological clus-
ter and not another. In reality there is a dense cloud of indi-
viduals in multidimensional space (or using the palette analo-
gy, a lot are sludgy brown) that is hard to divide. k-means
clustering forces individuals into one cluster, even if their
probability of being assigned to that cluster is only marginally
higher than being allocated to any of the other clusters. There
is a need to establish the stability of this allocation over time
and the reproducibility between populations. Furthermore,
whilst clustering may be conceptually useful, it can result in
loss of information when compared with using the continuous
data used to undertake the clustering. Dennis et al. recently
suggested that this is indeed the case [13]. These authors have
undertaken clustering in the ADOPT (A Diabetes Outcome
Progression Trial) clinical trial data and reproduced clusters
similar to those of Ahlqvist. However, whilst they showed that
the clusters are associated with differences in progression to
insulin treatment, time to insulin is better predicted simply by
including the age of diagnosis as a continuous measure into
the model [13].
Partitioned polygenic scoresAs outlined, above, there are now
known to be ~400 genetic variants associated with diabetes risk
and people who carry a lot of risk variants are at marked risk of
developing diabetes. These genetic variants are, by definition,
aetiological variants and in the context of the palette model
some people will develop diabetes as they have predominantly
a genetic defect in beta cell function, whilst others will have a
genetic defect in other pathways. Mahajan et al. partitioned 177
diabetes risk variants according to their association with meta-
bolic traits, resulting in six groups of variants each
characterised by a particular pathophysiological process [9].
A similar approach was undertaken by Udler et al. using 94
type 2 diabetes variants mapped to an extended range of met-
abolic and laboratory measures (including lipids, leptin,
adiponectin) and anthropometry (including fat distribution)
[14]. The resulting groups of variants (which when summed
together are termed partitioned polygenic scores [pPSs]) were
representative of five broad pathophysiological processes: clas-
sic beta cell deficiency with high proinsulin; beta cell deficien-
cy with low proinsulin; obesity; lipodystrophy and a process
characterised by fatty liver and abnormal lipids. Importantly,
these genetically defined processes mapped well to similar
physiological measures in individuals with type 2 diabetes. In
addition, the resulting pPS had differential associations with
outcomes (captured by population GWAS rather than in indi-
viduals with diabetes): the beta cell-deficient pPS was associ-
ated with coronary artery disease, ischaemic stroke and large
and small vessel disease; the lipodystrophy pPS was associated
with coronary artery disease, blood pressure and increased uri-
nary albumin/creatinine ratio.
Implications With increasingly large datasets of well-
characterised individuals with physiological measures and multi-
omic measures, and an increasingly large number of identified
diabetes risk variants, it is likely that we will be able to better
map the aetiological processes that contribute to diabetes risk
and map individuals within this space. For example, the IMI
DIRECT (Innovative Medicines Initiative Diabetes Research on
Patient Stratification) study has extensively characterised ~3000
people at different levels of blood glucose, including recently di-
agnosed type 2 diabetes, at baseline, at 18months and again at 3 or
4 years [15]. These participants had frequently sampled OGTTor
mixed-meal test, MRI to assess fat distribution, assessment of
incretin and glucagon secretion, diet and activity assessments
and multiple omics (RNA seq of blood, metabolomics [targeted
and untargeted], proteomics [O-link] and faecalmetagenomics). In
this way a large number of potential measures including lifestyle
measures can be used to tease out the aetiological processes that
may contribute to diabetes risk and diabetes outcomes.
Does an understanding of the processes that contribute to
type 2 diabetes and the relative contribution of these pro-
cesses for an individual have any implications? Certainly,
the genetic and clinical/physiological approaches have
identified individuals potentially at increased risk of com-
plications of diabetes and with different rates of progres-
sion. Thus we would anticipate that these clinical and ge-
netic factors can be combined in risk prediction models to
predict risk of diabetes progression (to failure of therapy or
need for insulin) or risk of complications.
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It would be interesting to see how deconvoluting the
aetiological mechanisms for type 2 diabetes impacts on treat-
ment response. Do individuals with diabetes who have a high
lipodystrophy pPS have greater response to thiazolidinediones?
Do those with a high beta cell deficiency pPS have altered
response to sulfonylureas? This was recently demonstrated
when these processes were captured by direct physiological
measurement. In a clustering analysis of the ADOPT and
RECORD (Rosiglitazone Evaluated for Cardiac Outcomes
and Regulation of Glycaemia in Diabetes) studies, the
insulin-resistant cluster responded better to thiazolidinediones
and the older-patient cluster responded better to sulfonylureas
[13]. However, it should be noted that, in this study, simply
using age, sex, BMI and HbA1c as continuous measures was
much better at predicting treatment response than assigning
individuals to specific clusters [13].
Type 2 diabetes in non-white ethnic
populations
This review, and indeed the bulk of the literature, largely over-
looks the fact that most people with diabetes are of non-white
ethnicity. What is clear is that the South Asian, East Asian and
African diabetes phenotypes are markedly different from
those of white populations. Whilst there are studies investigat-
ing the genetics and pathophysiology of diabetes in these pop-
ulations, they are much less comprehensive than seen to date
in white people. If we are truly to understand the many faces
of type 2 diabetes, we need to focus on large-scale phenotyp-
ing and genotyping studies, mapped to treatment outcome and
long-term outcome in these non-white populations.
Type 2 diabetes: a multifaceted disease
Type 2 diabetes is a truly complex disease! In the broader
sense, due to diagnostic challenges, it is a mix of different
clearly defined aetiologies that we need to be better at identi-
fying as this has major implications for treatment and patient
management. Beyond this, type 2 diabetes is a complex dis-
ease driven by multiple pathophysiological processes
resulting in a spread of clinical characteristics that to date are
largely ignored when considering how we manage affected
individuals. Whilst it may turn out to be clinically useful to
group individuals with type 2 diabetes into subtypes based
upon the main processes driving their diabetes, the case for
this has not yet been made. It seems more likely that using
continuous clinical and physiological measures, possibly
combined with pPSs, is likely to be more valuable in
predicting outcomes and guiding management.
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